COVID-19: What could happen next? 9 Dec Forum video

COVID-19: What could happen next? forum video

Monash University's Central Clinical School and community organisation Maccabi Life partnered to present a public forum on 9 Dec 2020, "COVID-19: What could happen next?", MC'd by Professor Terry O'Brien. 

The forum featured Professor Paul Zimmet AO, talking about the new CoviDIAB registry which is tracking patients with first-time onset diabetes; and Drs Elspeth Hutton and Robb Wesselingh talking about the new NeuroCOVID registry being set up to track patients with neurological complications.  Professor Christina Mitchell AO, Dean of Monash's Faculty of Medicine, Nursing and Health Sciences, gave an introduction. See links to the time of their presentations below, and also the audience questions.

COVID-19: What could happen next? Join our 9 Dec forum to find out more

Register here for the 9 Dec forum, 7-8 pm

What happens next with COVID-19? It's complicated... Once infected with COVID-19, the illness can cause devastating complications which we don't yet understand. Register here for our 9 Dec forum

A forum, "COVID-19: What could happen next?" on 9 Dec at 7-8 pm will give you the chance to hear from our panel of diabetes and neurology experts on the urgent need to know the extent and causes of new-onset and dysfunction with diabetes and neurological conditions. They'll outline how registries are vital to provide the best interventions and management for treatment, and to understand the potential longer-term impact on the health of people who have been infected.

New drug hope for migraine sufferers

A recent study by Monash University neuroscientists has shown the effectiveness of a migraine drug called Erenumab (Aimovig) for chronic sufferers, which sadly remains unaffordable for most patients.

Involving 170 patients living with frequent, severe migraine attacks (chronic migraine) across three specialist headache centres in Australia, findings revealed that after being prescribed Erenumab, after three months 58.8 per cent had at least halved the number of ‘migraine attack’ days each month. This result was maintained at six months, with 50 per cent experiencing half the number of days with migraine that they had at baseline.

Dr Elspeth Hutton: The burden of the 'suicide' headache

Dr Elspeth Hutton, Research Fellow
Department of Neuroscience

They’re called suicide headaches because the pain is frequent and unbearable.

Commonly known as cluster headaches, they can occur up to eight times a day. They start suddenly, last for up to three hours, and can be very painful. A bout of regular attacks, known as a cluster bout, can last weeks to months.